Mustang inks a deal for in vivo CAR-T tech from the Mayo Clinic; How a spilled cup of tea landed one biotech $11.7 million
As part of its push to develop an off-the-shelf CAR-T therapy, Mustang Bio has inked a deal for new technology out of the Mayo Clinic designed to form CAR-T cells inside the patient.
The two-step approach comes from the lab of Larry Pease, principal investigator and former director of the Mayo Clinic’s Center for Immunology and Immune Therapies. First, the patient receives a peptide that drives the rapid reproduction of the body’s own resident T cells. Then, a viral CAR construct is administered directly into the patient’s lymph nodes. That construct infects the activated T cells, and essentially forms CAR-T cells in vivo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.